Remus Pharmaceuticals Ltd (REMUS) is currently trading at 928.85 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Remus Pharmaceuticals Limited is a rapidly growing pharmaceutical company established in 2015, specializing in the marketing and distribution of niche off-patent formulations. The company operates an asset-light model, boasting a portfolio of over 800 approved products across major therapeutic segments such as oncology and cardiology, and serves more than 40 countries. In 2024, Remus expanded into the U.S. market through the acquisition of Espee Global Holdings LLC, solidifying its presence in the specialty and biosimilar drugs sector. The company's strategy involves robust partnerships with multinational pharmaceutical firms, allowing for expanded market reach through Channel Partners for governmental and institutional tenders. Investments in R&D focus on expanding their product portfolio, targeting new territories while aiming to achieve first-mover advantages in off-patent drugs.

Over the past 52 weeks, Remus Pharmaceuticals Ltd has traded between a low of ₹580.00 and a high of ₹987.50. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Remus Pharmaceuticals Ltd has a market capitalization of approximately 1,075.58. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Remus Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 29.08 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,075.58 Cr, Remus Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Remus Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Remus Pharmaceuticals Ltd is 29.08. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.